Molecular targets of botulinum toxin at the mammalian neuromuscular junction

Movement Disorders

Volumn 19, Issue SUPPL. 8, 2004, Pages

  Whelchel, Dorothy D ^a   Brehmer, Tonia M ^a   Brooks, Paula M ^a   Darragh, Neely ^a   Coffield, Julie A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Botulinum neurotoxin; Neuromuscular junction; Paralysis; SNAP 25; Sprouting; VAMP

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; MEMBRANE PROTEIN; NEUROTRANSMITTER; SNARE PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; NERVE PROTEIN; NEUROTOXIN; SNAP25 PROTEIN, MOUSE; SYNAPTOBREVIN; VESICULAR TRANSPORT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DISEASE COURSE; DRUG DIFFUSION; DRUG MECHANISM; DRUG TARGETING; GASTROCNEMIUS MUSCLE; HINDLIMB; IMMUNOHISTOCHEMISTRY; LEG MUSCLE; MALE; MEMBRANE VESICLE; MORTALITY; MOTOR DYSFUNCTION; MOUSE; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; METABOLISM; METHODOLOGY; MOTOR ACTIVITY; MUSCLE; SYNAPTOSOME; TIME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BOTULINUM TOXINS; MALE; MEMBRANE PROTEINS; MICE; MOTOR ACTIVITY; MUSCLES; NERVE TISSUE PROTEINS; NEUROMUSCULAR JUNCTION; NEUROTOXINS; R-SNARE PROTEINS; SNARE PROTEINS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; SYNAPTOSOMES; TIME FACTORS; VESICULAR TRANSPORT PROTEINS;

EID: 2942520007     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20004     Document Type: Article

References (42)

1. Cato EP, George WL, Finegold SM. Genus Clostridium. In: Sneath PHA, Mair NS, Sharpe ME, et al. editors. Bergey's manual of systematic bacteriology. Vol. 2. Baltimore: Williams and Wilkins; 1986. p 1141-1200.
2. Hatheway CL. Bacterial sources of clostridial neurotoxins. In: Simpson LL, editor. Botulinum neurotoxin and tetanus toxin. New York: Academic Press; 1989. p 3-24.
3. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:717-766.
4. Center for Disease Control and Prevention, National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases. Botulism in the United States, 1899-1996, Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, GA: Center for Disease Control; 1998.
5. DasGupta BR, Sugiyama HA. A common subunit structure in Clostridium botulinum type A, B, and E toxins. Biochem Biophys Res Commun 1972;48:108-112.
6. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998;5:898-902.
7. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. J Physiol 1949;109:10-24.
8. Kao I, Drachman DB, Price DL. Botulinum toxin: mechanism of presynaptic blockade. Science 1976;192:1256-1258.
9. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 1986;11:314-317.
10. Halpern JL, Neale EA. Neurospecific binding, internalization and retrograde axonal transport. Curr Top Microbiol Immunol 1995; 195:221-241.
11. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000;7:693-699.
12. Söllner T, Bennett MK, Whiteheart S, Scheller RH, Rothman JE. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993;75:409-418.
13. Schiavo B, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992;359:832-835.
14. Schiavo G, Rossetto O, Catsicas S, Delaureto PP, DasGupta BR, Benefenati F, Montecucco C. Identification of the nerve terminal targets of botulinum neurotoxin serotype-A, serotype-D, and serotype-E. J Biol Chem 1993;68:23784-23787.
15. Schiavo G, Shone DD, Rossetto O, Alexander FCG, Montecucco CL. Botulinum neurotoxin serotype-F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 1993;268:11516-11519.
16. Schiavo G, Malizio C, Trimble WS, Polverino de Laureto P, Milan G, Sugiyama H, Johnson EA, Montecucco C. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem 1994;269:20213-20216.
17. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365: 160-163.
18. Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, Jahn R. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J 1993;12:4821-4828.
19. Jankovic J, Brin MF. Botulinum toxin: historical perspectives and potential new indications. Muscle Nerve 1997;20(Suppl. 6):S129-S145.
20. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997;40:317-327.
21. Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol Ther 1996;72:13-24.
22. Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G, Graham HK. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trail. Dev Med Child Neurol 2000; 42:116-121.
23. Göbel H, Axel H, Heinze-Kuhn K, Austermann K. Botulinum toxin A in treatment of headache symptoms and pericranial pain syndromes. Pain 2001;91:195-199.
24. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-254.
25. Adler CH, Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology 2000;55(Suppl. 5):S9-S14.
26. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000;55(Suppl. 5):S29-S35.
27. Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 1997;28:1440-1466.
28. Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, Shapira AHV, Marsden CD. Generalized muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999;67:90-93.
29. Eleopra R, Tugnoli V, Caniatti L, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46:1158-1160.
30. Kalandakanond S, Coffield JA. Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue. J Pharmacol Exp Ther 2001;296:749-755.
31. Kalandakanond S, Coffield JA. Cleavage of SNAP-25 by botulinum toxin A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J Pharmacol Exp Ther 2001:296:980-986.
32. Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. Toxicon 2001;39: 1309-1315.
33. Raciborska DA, Trimble WS, Charlton MP. Presynaptic protein interactions in vivo: evidence from botulinum A, C, D, and E at the frog neuromuscular junction. Eur J Neurosci 1998;10:2617-2628.
34. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39:1815-1820.
35. Duchen LW. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 1970;33:40-54.
36. Angaut-Petit D, Molgó J, Comella JX, Faille L, Tabti N. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 1990;37:799-807.
37. Angaut-Petit D, Molgó J, Faille L, Juzans P, Takahashi M. Incorporation of synaptotagmin II to the axolemma of botulinum type-A poisoned mouse motor endings during enhanced quantal acetylcholine release. Brain Res 1998;797:357-360.
38. Comella JX, Molgó J, Faille L. Sprouting of mammalian motor nerve terminals induced by in vivo injection of botulinum type-D and the functional recovery of paralysed neuromuscular junctions. Neurosci Lett 1993;153:61-64.
39. Juzans P, Comella JX, Molgó J, Failee L, Angaut-Petit D. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul Disord 1996;6:177-185.
40. de Paiva A, Meunier FA, Molgó J, Aoki JR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999;96: 3200-3205.
41. Keller JE, Neale EA, Olyer G, Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 1999; 456:137-142.
42. Adler M, Keller JE, Sheridan RE, Deshpande SS. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 2001;39:233-243.